Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 results, is ...

The acquisition of Vyrsa Technologies in December 2023 allowed Nevro to introduce a complementary line of products to treat chronic pain caused by the SI joint. By adding this product line ...

(NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is ...

sustain demand for products, (v) compete successfully (including without limitation success in convincing surgeons to use Globus Medical or Nevro products and the ability to attract and retain ...

trends in the medical industry and the ability of Globus Medical and Nevro to: (i) successfully integrate and achieve anticipated synergies, (ii) manage our growth, (iii) sustain profitability, (iv) ...

AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition ...